Amy joined Oxford Science Enterprises in March 2021. She focusses on uncovering new opportunities in Health Tech, as well as supporting the creation of new businesses and the existing portfolio.
Prior to OSE, Amy worked as a M&A strategy consultant at EY Global, helping clients define acquisition targets to future proof their businesses. Before this, Amy worked in corporate innovation at Merck KGaA supporting the development of early-stage ideas in liquid biopsy and biosensors.
Amy has also worked on numerous software and AI grassroots concepts that have received recognition from Global leaders including the European Space Agency, European Institute of Innovation and Technology, and EY Global Innovation. Her academic work in the gut-brain axis has been published in Nature’s Translational Psychiatry and other high impact journals including Schizophr Res, Neuropharmacology, and Psychoneuroendocrinology.
Amy holds a DPhil in Neuroscience from the University of Oxford.
